Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2001

View Archived Issues

CS-023 may have advantages over imipenem and meropenem according to preclinical data

Inhibition of PI3K enhances human sperm motility

AGI-1067 advances to phase IIb for treatment of restenosis and atherosclerosis

Targeted anti-Gram-positive oxazolidinone shows promise for resistant infections

Oritavancin phase III data, potential in anthrax infections discussed at ICAAC meeting

Adjunctive therapy with Actimmune in a serious invasive fungal infection

Vasomax amendment submitted in the U.K.

Pharmacia returns U.S. rights to Ambien to Sanofi-Synthelabo

Schering-Plough highlights promising therapeutics in development pipeline

Amylin anticipates filing NDA amendment for Symlin within the next six months

Salix seeks approval for rifaximin in travelers' diarrhea

Tularik presents SAR in a novel class of non-nucleoside anti-HCMV agents at ICAAC meeting

AstraZeneca and Lilly to collaborate on clinical trials with ZD-1839 and gemcitabine combination

Allopurinol reverses mechanoenergetic uncoupling in cardiomyopathy

Muscarinic agonist identified at Acadia reduces intraocular pressure in monkeys

New antiinflammatory steroids useful for asthma and various other conditions

N/OFQ receptor ligands useful as analgesics discovered by GSK

Boehringer Ingelheim patents compounds for asthma and other inflammatory disorders

Glycopeptide antibacterial agents designed by Merck

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...